Advertisement
Advertisement

CRVS

CRVS logo

Corvus Pharmaceuticals Inc

4.91
USD
+0.36
+7.91%
Dec 24, 12:59 UTC -5
Closed
...

Corvus Pharmaceuticals Inc Profile

About

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Info & Links

CEO

Richard A. Miller

Headquarters

863 Mitten Road, Suite102
BURLINGAME, CA 94010, UNITED STATES

Industry

Pharmaceuticals Major

Sector

Health Technology

Website

www.corvuspharma.com

Auditor

PricewaterhouseCoopers LLP

Share holders

16

Employees

28

Corvus Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

315.52M

Enterprise Value

310.84M

Enterprise Value/EBITDA(ttm)

-11.94

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

25.15

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-70.71%

Return on Invested Capital(ttm)

-366.70%

Return on Assets(ttm)

-45.90%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-26.03M

Net Income Available to Common(ttm)

-56.83M

Diluted EPS(ttm)

-0.93

Share Statistics

Beta (5Y Monthly)

1.05

52-Week Change

203.09%

S&P 500 52-Week Change

26.50%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

64.26M

Dividend Yield

0.00%

Float4

44.15M

% Held by Insiders

31.30%

% Held by Institutions

46.64%

Balance Sheet

Total Cash(mrq)

41.65M

Total Cash Per Share(mrq)

0.65

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

0.92%

Quick Ratio(mrq)

0.92%

Book Value Per Share(mrq)

0.20

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.25

Free Cash Flow(ytd)

-16.96M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement